Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.

Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.

Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.

Three years after its last misfire, Israeli biotech PolyPid is having another go at a Nasdaq listing, seeking $86 million to develop anti-infectives.

Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.

ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental med against RSV.

Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.

Solid Bio has pressed on after its plans for an IPO fell apart—with a cut-price offering for an upsized stake.

Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.